Thomas Milz
Corporate Officer/Principal at APONTIS PHARMA AG
Thomas Milz active positions
| Companies | Position | Start | End |
|---|---|---|---|
| APONTIS PHARMA AG | Corporate Officer/Principal | 31/12/2020 | - |
PP Apontis Pharma GmbH
 PP Apontis Pharma GmbH Financial ConglomeratesFinance PP Apontis Pharma GmbH is an investment holding German company. The company is based in Monheim am Rhein, Germany. The CEOs are Thomas Milz and Thomas Zimmermann. The private company was founded in 2019. | Chief Executive Officer | 30/04/2021 | - |
Career history of Thomas Milz
Former positions of Thomas Milz
| Companies | Position | Start | End |
|---|---|---|---|
Apontis Pharma GmbH & Co. KG
 Apontis Pharma GmbH & Co. KG Pharmaceuticals: MajorHealth Technology APONTIS PHARMA Deutschland GmbH & Co. KG engages in the wholesale of pharmaceutical products. It focuses on medicines used for the treatment of chronic obstructive pulmonary diseases, hypertension, and cardiovascular diseases. The company was founded on February 13, 2015 and is headquartered in Monheim, Germany. | Corporate Officer/Principal | 31/12/2016 | 31/12/2017 |
UCB Pharma GmbH
 UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Corporate Officer/Principal | 31/12/2006 | 31/12/2015 |
| Schwarz Pharma Deutschland GmbH | Corporate Officer/Principal | 31/12/1996 | 31/12/1998 |
| Sales & Marketing | 31/12/1998 | 31/12/2006 | |
| Sanol GmbH | Sales & Marketing | 31/12/1998 | 31/12/2006 |
| Madaus AG | Corporate Officer/Principal | 31/12/1995 | 31/12/1996 |
UCB Pharma GmbH
UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Corporate Officer/Principal | 31/12/1992 | 31/12/1995 |
Training of Thomas Milz
| Fachhochschule Düsseldorf | Undergraduate Degree |
Statistics
International
| Germany | 9 |
Operational
| Corporate Officer/Principal | 6 |
| Sales & Marketing | 2 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| APONTIS PHARMA AG | Health Technology |
| Private companies | 6 |
|---|---|
UCB Pharma GmbH
UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Health Technology |
| Schwarz Pharma Deutschland GmbH | |
Apontis Pharma GmbH & Co. KG
Apontis Pharma GmbH & Co. KG Pharmaceuticals: MajorHealth Technology APONTIS PHARMA Deutschland GmbH & Co. KG engages in the wholesale of pharmaceutical products. It focuses on medicines used for the treatment of chronic obstructive pulmonary diseases, hypertension, and cardiovascular diseases. The company was founded on February 13, 2015 and is headquartered in Monheim, Germany. | Health Technology |
PP Apontis Pharma GmbH
PP Apontis Pharma GmbH Financial ConglomeratesFinance PP Apontis Pharma GmbH is an investment holding German company. The company is based in Monheim am Rhein, Germany. The CEOs are Thomas Milz and Thomas Zimmermann. The private company was founded in 2019. | Finance |
| Sanol GmbH | |
| Madaus AG |
- Stock Market
- Insiders
- Thomas Milz
- Experience
